
Pfizer Inc.
PFE
Updated: 23/09/2026, 09:42:11
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
No summaries found.
The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.
- Share price
- $27.93
- Market cap
- $159.19B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Albert Bourla
- Employees
- 75,000
- IPO date
- 01/06/1972
- Beta
- 0.299
- Last dividend
- $0.00
- Day range
- $27.50 – $27.99
- 52-week range
- $23.58 – $29.21
- 1-day performance
- 0.68%
- 1-year performance
- 18.45%
- Current drawdown (1Y)
- -4.38%
- CIK
- 0000078003
- CUSIP
- 717081103
- ISIN
- US7170811035
- Created
- 07/12/2025, 05:43:26
- Last update
- 23/09/2026, 09:42:11
Track Pfizer Inc. with an AI analyst
See which prediction-market events move PFE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees
24/7 Wall Street • STOCK • 11/06/2026, 16:26:07
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
24/7 Wall Street • STOCK • 11/06/2026, 16:23:39
Prediction: Pfizer Stock Will Double on This Date
24/7 Wall Street • STOCK • 10/06/2026, 04:06:09
RBC Capital Upgrades Pfizer (NYSE: PFE) Amid Positive Drug Developments
Market Data • Market Data • 10/06/2026, 00:18:39
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
Zacks Investment Research • STOCK • 09/06/2026, 15:20:32
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 13:48:30
Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge
Seeking Alpha • STOCK • 08/06/2026, 09:04:32
US FDA approves Pfizer's bleeding disorder drug for children
Reuters • STOCK • 08/06/2026, 08:49:21
3 Dividend Stocks to Buy Hand Over Fist in June
The Motley Fool • STOCK • 07/06/2026, 03:30:00
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.
The Motley Fool • STOCK • 06/06/2026, 15:32:00
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
The Motley Fool • STOCK • 06/06/2026, 14:15:00
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Reuters • STOCK • 06/06/2026, 11:06:33